.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,770,759

« Back to Dashboard

Details for Patent: 5,770,759

Title: Prostaglandins of the F series
Abstract:The present invention provides new compounds, 13,14-dihydro-15-keto-PGFs, and vassopressors containing them, which raise blood pressure without substantial ephemeral depression of blood pressure, trachea or enteron contraction effect inherent in usual PGFs.
Inventor(s): Ueno; Ryuzo (Nishinomiya, JP), Ueno; Ryuji (Nishinomiya, JP), Oda; Tomio (Itami, JP)
Assignee: R-Tech Ueno, Ltd. (Osaka-Fu, JP)
Filing Date:Aug 23, 1996
Application Number:08/701,865
Claims:1. A 13,14-dihydro-15-keto-PGF represented by the formula:

in which a bond between C-2 and C-3 is a single or a double bond, X is a group: ##STR37## R.sub.1 is a hydrogen atom or a C.sub.1-4 alkyl, phenyl, benzoyl, hydroxyalkyl, alkoxyalkyl, trialkylsilyl or tetrahydropyranyl group;

R.sub.2 is a hydrogen atom or a lower alkyl group;

R.sub.3 is hydroxyl;

R.sub.3' is hydroxyl; R.sub.4 and R.sub.5 are independently a hydrogen atom or a lower alkyl group, R.sub.6 is a C.sub.1-9 alkyl group containing a C.sub.1-2 alkoxy substituent or ##STR38## (wherein R.sub.7 is a hydrogen or halogen atom or a halogenated methyl group; and a physiologically acceptable salt of said 13,14-dihydro-15-keto-PGF.

2. The 13,14-dihydro-15-keto-PGF of claim 1, wherein R.sub.1 is a C.sub.1-4 alkyl group.

3. The 13,14-dihydro-15-keto-PGF according to claim 1, wherein at least one of R.sub.4 and R.sub.5 is a lower alkyl group, or a physiologically acceptable salt thereof.

4. The 13,14-dihydro-15-keto-PGF of claim 1 comprising a 13,14-dihydro-15-keto-16-substituted-PGF represented by the formula: ##STR39## or a physiologically acceptable salt thereof.

5. The 13,14-dihydro-15-keto-PGF according to claim 1, wherein each of R.sub.4 and R.sub.5 is a lower alkyl group, or a physiologically acceptable salt thereof.

6. The 13,14-dihydro-15-keto-PGF according to claim 1, comprising a 13,14-dihydro-15-keto-16-desbutyl-16-trifluoromethyl-phenoxy-PGF or a physiologically acceptable salt thereof.

7. A 13,14-dihydro-15-keto-PGF represented by the formula: ##STR40## in which a bond between C-2 and C-3 is a single or a double bond, X is a group: ##STR41## R.sub.1 is a hydrogen atom or a C.sub.1-4 alkyl, phenyl, benzoyl, hydroxyalkyl, alkoxyalkyl, trialkylsilyl or tetrahydropyranyl group;

R.sub.2 is a hydrogen atom or a lower alkyl group;

R.sub.3 is hydroxyl;

R.sub.3' is hydroxyl; R.sub.4 and R.sub.5 are independently a hydrogen atom or a lower alkyl group, R.sub.6 is a c.sub.6-9 alkyl group which may be branched or contain a double bond; and a physiologically acceptable salt of said 13,14-dihydro-15-keto-PGF.

8. The 13,14-dihydro-15-keto-PGF of claim 7, wherein R.sub.1 is a C.sub.1-4 alkyl group.

9. The 13,14-dihydro-15-keto-PGF according to claim 7, wherein at least one of R.sub.4 and R.sub.5 is a lower alkyl group, or a physiologically acceptable salt thereof.

10. The 13,14-dihydro-15-keto-PGF according to claim 7, wherein each of R.sub.4 and R.sub.5 is a lower alkyl group, or a physiologically acceptable salt thereof.

11. A 13,14-dihydro-15-keto-20-ethyl-PGF represented by the formulae: ##STR42## in which a bond between C-2 and C-3 is a single or a double bond, X is a group: ##STR43## R.sub.1 is a hydrogen atom or a C.sub.1-4 alkyl, phenyl, benzoyl, hydroxyalkyl, alkoxyalkyl, trialkylsilyl or tetrahydropyranyl group;

R.sub.2 is a hydrogen atom or a lower alkyl group;

R.sub.3 is hydroxyl;

R.sub.3' is a hydroxyl; R.sub.4 and R.sub.5 are independently a hydrogen atom or a lower alkyl group or a physiologically acceptable salt thereof.

12. A 13,14-dihydro-15-keto-PGF of claim 7 being a 13,14-dihydro-15-keto-20-ethyl-PGF.sub.1.alpha., a C.sub.1 -C.sub.4 alkyl ester or a physiologically acceptable salt thereof.

13. A 13,14-dihydro-15-keto-PGF of claim 7 being a 13,14-dihydro-15-keto-20-ethyl-PGF.sub.1.alpha. isopropyl ester.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc